Applied DNA Sciences (NASDAQ:APDN) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a research report sent to investors on Friday. The brokerage issued a sell rating on the technology company’s stock.

Separately, HC Wainwright reduced their price target on Applied DNA Sciences from $7.00 to $1.50 and set a buy rating on the stock in a research note on Monday, June 10th.

Applied DNA Sciences Stock Performance

APDN stock opened at $0.47 on Friday. Applied DNA Sciences has a 1 year low of $0.42 and a 1 year high of $37.20. The stock’s 50 day moving average price is $2.57 and its 200 day moving average price is $8.23. The firm has a market cap of $456,680.00, a P/E ratio of -0.03 and a beta of 0.08.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings results on Friday, May 10th. The technology company reported ($5.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.60) by ($0.71). Applied DNA Sciences had a negative return on equity of 306.32% and a negative net margin of 222.33%. The business had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.90 million. On average, research analysts predict that Applied DNA Sciences will post -2.95 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC purchased a new stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned approximately 0.72% of Applied DNA Sciences at the end of the most recent quarter. Hedge funds and other institutional investors own 22.22% of the company’s stock.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.